Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

Will buyers go after Mylan once it inverts? Don’t count on it, analyst says

December 3, 2014
Life sciences
As Mylan gears up to close a $5.3 billion deal to buy a chunk of Abbott’s generics business and shift its tax base to the Netherlands, some investors are speculating it could itself become a target for another stateside company looking for a tax inversion. But to that, Sanford Bernstein analyst Tim Anderson says they shouldn’t hold their breath.
 
The reason? Most of the company’s likely suitors don’t actually make that good a match, he wrote in a Tuesday note to clients. Take Pfizer, for example, which has been jonesing for a tax inversion since this spring’s failed play for British pharma giant AstraZeneca. Mylan will be too small to help the company complete one, Anderson notes, as foreign targets must be at least 20% of the buyer’s size.
 
And then there’s Teva, for whom the Mylan could be too large to swallow. With a market cap of $48 billion, Teva would need to make more than a couple significant divestments–like Epipen, which generates about 30% of Mylan’s profits–to afford the Pennsylvania drugmaker, whose own market cap is $22 billion, Anderson points out.
 
“Buying Mylan would mean the company will commit to a different direction than what it was apparently planning on,” he said.
 
If any interested buyers do go after Mylan, they’ll have to take heed of the company’s strategic plan to lift its share price to $73 by 2018–a 26% premium to its current price. “We do not see the board of the company accepting a lower offer,” he wrote.
 
Of course, “one should never say never about transactions,” he said, and that doesn’t mean both Pfizer and Teva won’t be pursuing other targets too–inversion or no inversion. Analysts figure Pfizer needs to make a move in the near-term, and some industry watchers think it could still come back and make another run at AZ. As for the Israeli generics behemoth, it’s been scouting for deals in the $10 billion to $15 billion range, Anderson says. Pickups could potentially help Teva toward its stated goals of widening its emerging markets footprint and becoming a biosimilars contender.
 
By Carly Helfand
 

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

Read more
April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

Read more
April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

Read more
More news

How can we help you?

We're easy to reach